A Blood Test to Predict Alzheimer’s Staging
A new study demonstrates that a simple blood test measuring phosphorylated tau (p-tau217) can accurately predict the pathological stage of Alzheimer’s disease, as determined by expensive and less accessible PET scans. The plasma biomarker showed excellent performance in detecting early amyloid and intermediate tau pathology, with researchers identifying specific concentration thresholds that could define a “therapeutic window” for intervention. This work suggests that accessible blood-based biomarkers could reliably identify optimal candidates for emerging disease-modifying therapies.
Why it might matter to you:
The push towards accessible, precise biomarkers for neurological disease staging directly parallels the need for similar tools in neurodevelopmental research. This study exemplifies a translational pathway from complex imaging to a scalable blood test, a methodological shift that could inform how you approach biomarker discovery for early detection in your own field. Understanding these biological transition points is crucial for designing future prevention trials, a concept highly relevant to research on disorders with developmental origins.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
